Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
about
Mepolizumab versus placebo for asthmaOmalizumab for asthma in adults and childrenAnti-IgE for chronic asthma in adults and childrenImmunological mechanisms of allergen-specific immunotherapyImmunoglobulin E-mediated airway inflammation is active in most patients with asthma.Syk expression in peripheral blood leukocytes, CD34+ progenitors, and CD34-derived basophils.Circulating conventional and plasmacytoid dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in atopic subjects.Regulation of Syk kinase and FcRbeta expression in human basophils during treatment with omalizumab.Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challenge.Omalizumab in the treatment of asthma.Comparative study of Korean White Ginseng and Korean Red Ginseng on efficacies of OVA-induced asthma model in miceEfficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study.Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.Janus kinase-3 dependent inflammatory responses in allergic asthmaIgE expression pattern in lung: relation to systemic IgE and asthma phenotypes.A Study of Agastachis Herba on Ovalbumin-induced Asthma in the Mouse.The impact of comorbid atopic disease on asthma: clinical expression and treatment.Anti-immunoglobulin e therapyImmunoglobulin E blockade in the treatment of asthma.Omalizumab for treatment of allergic rhinitis.Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Severe asthma and the omalizumab option.Anti-IL5 therapies for asthma.Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.
P2860
Q24186306-1F013D9E-5A4E-49FF-A693-108348779455Q24201145-A3684996-C8B7-4E4F-AC53-D6E9E1828DE6Q24246484-1F957237-607B-43CA-BDBA-D66619319B4BQ28265326-CEDDE871-D809-466E-80DF-8311A2CF42C9Q30444397-CA20E28F-6E2B-4E9B-8CAD-677ABF5FF732Q33615243-E1894B95-A397-4D60-8A8D-BAFF04843C89Q33616522-762AD2F5-9509-4D5B-A836-FF805733A127Q33774660-25FA2257-C448-43A4-AD00-ECC382DFC186Q33774675-5891816B-C2B1-4265-A4E7-562D3C54E6C8Q34029374-CC6FBDF2-CB14-4B15-A0BF-0E2FEE58BB2EQ34719357-B00CAC1C-83A4-444E-9CAD-B0529309028FQ34727734-3FE8BA41-23EC-4C67-BCF3-AE6B420C9AE7Q34979344-A54A784C-ED0B-4852-A966-F4F0E3FFB20CQ35031161-64037EA7-77B6-4381-A0E9-99822D698CCFQ35867469-73874289-E178-47E3-9AD2-576C6B3D0E53Q36428798-EACE6BF9-260C-4612-9355-71A17B0B57B1Q36799761-2766AE55-4910-469F-99EF-E6988AB59F64Q36834564-B8E59C70-19C2-474F-86ED-26B5938B52FEQ36951998-29B8A3C9-4F19-48DE-83F4-C14DB1490883Q38101972-3389868C-E5AD-49A4-9199-D209CC20F173Q39012896-E72BD999-78FF-4C8E-8C85-75E834543E7FQ40740336-A6F13B7B-137E-4870-9BD3-3A9ABBA06D5BQ47551081-AD96AC8E-430D-4CB9-BBA1-91AC8CC746BFQ55277398-935C012A-1B50-4EE2-B2B1-9D2159D8C0AE
P2860
Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@ast
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@en
type
label
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@ast
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@en
prefLabel
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@ast
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@en
P2093
P1476
Anti-IgE (omalizumab) inhibits ...... epeat skin allergen challenge.
@en
P2093
A Barry Kay
Andrew Menzies-Gow
Farid Benyahia
Julia Barkans
Tsen-Teng Ou
Yee Ean Ong
P304
P356
10.1016/J.JACI.2005.05.035
P407
P577
2005-09-01T00:00:00Z